Oregon Department of Transportation officials aren't expected to offer a formal recommendation on what to do about the $500 million freeway project.

Detailed price information for Pliant Therapeutics Inc (PLRX-Q) from The Globe and Mail including charting and trades.

Following the DSMB's previously announced recommendation, Pliant voluntarily paused enrollment and dosing in the BEACON-IPF clinical trial. Pliant is committed to remaining blinded ensuring the data ...